Towa Pharmaceutical : FY2023(1st quarter) Supplementary Material of Financial Results (1.03M/28P)
August 10, 2023 at 02:23 am EDT
Share
Supplementary material for the financial results for
the first quarter of the year ending March 31, 2024
August 2023
(Stock code: 4553)
2023
Notes to and summary of the disclosure of financial results for 2024/03 1Q
Notes
Due to the change in the fiscal year end of Towa HD and Sunsho Pharmaceuticals in the consolidated financial statements for the fiscal year ending March 31, 2023, the first quarter of the fiscal year ending March 31, 2024 for these subsidiaries is from April 1, 2023 to June 30, 2023.
In order to compare the financial results of Towa HD and Sunsho Pharmaceuticals for 2024/03 1Q with the same months of the previous year, the financial results for 2023/03 1Q are disclosed as reference values, replacing the consolidated cumulative period from January 1 to March 31, 2022 with the period from April 1 to June 30, 2022.
In this document, the term "23/03 1Q (period adjustment)" is used.
For the convenience of yen conversion of local currency basis figures, Towa HD's financial results for "23/03 1Q (period adjustment)" are calculated by subtracting the yen-based results for the period from January 1, 2022 to March 31, 2022 from the yen-based results for the period from January 1, 2022 to June 30, 2022.
Therefore, even if "23/03 1Q (period adjustment)" is converted into yen using the Euro-Yen exchange rate for the period from April 1 to June 30, 2022, it will not be equal to the financial results for the period from April 1 to June 30, 2022 on a local currency basis.
2023
1
Notes to and summary of the disclosure of financial results for 2024/03 1Q
Summary
●Overall consolidated net sales and income increased year on year.
2024/03 1Q
2023/03 1Q (period adjustment)
2023/03 1Q
Fiscal period
(Overseas & Sunsho,
(Overseas & Sunsho,
(Overseas & Sunsho,
from April 2023 to June 2023)
from April 2022 to June 2022)
from January 2022 to March 2022)
Item
(JPY billion)
YOY change (%)
(JPY billion)
(JPY billion)
YOY change (%)
Net sales
54.5
+ 18.1
46.1
45.3
+ 5.7
Operating
4
+130.2
1.7
1.8
- 69.8
profit
Production volume ( Non-consolidated; tablets and capsules only )
Approx. 3.4 billion tablets, up approx. 22.0% year on year
Sales volume ( Non-consolidated; tablets and capsules only )
Approx. 3.23 billion tablets, up approx. 15.4% year on year
Increases in raw material costs and utilities expenses ( Non-consolidated )
Raw materials: Increased by several percentage points year on year due to higher resource prices and a weaker yen
Utilities expenses: Increased by approx. 37.6% year on year. The ratio of utilities costs to total production costs is about 2.5%.
2023
2
Contents
Outline of financial results for 2024/03 1Q
Outline of financial results for 2024/03 1Q - Progress rate
Balance sheets, capital expenditure and depreciation
2023
3
Contents
1. Outline of financial results for 2024/03 1Q
Consolidated
Segment information
Domestic segment
Breakdown
Net sales by supplement year (Non-consolidated)
Net sales by distribution channel (Non-consolidated)
Number of customers by customer segment (Non-consolidated)
Selling, general and administrative expenses (Domestic segment)
Overseas segment
By region
Outline of financial results for 2024/03 1Q - Progress rate
Balance sheets, capital expenditure and depreciation
2023
4
Attachments
Original Link
Original Document
Permalink
Disclaimer
TOWA Pharmaceutical Co. Ltd. published this content on 10 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2023 06:22:15 UTC.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
TOWA PHARMACEUTICAL CO., LTD. 
